Journal of Psychopharmacology
January 16, 2020
Lea J. Mertens, Matthew B. Wall, Leor Roseman et al.
211 citations
Background: Psilocybin has shown promise as a treatment for depression but its therapeutic mechanisms are not properly understood. In contrast to the presumed actions of antidepressants, we recently found increased amygdala responsiveness to fearful faces one day after open-label treatment with psilocybin (25 mg) in 19 patients with treatment-resistant depression, which correlated with...
2020
R. Zeifman, A. Wagner
Abstract Borderline Personality Disorder (BPD) is a severe psychiatric disorder characterized by behavioral dysregulation, emotion dysregulation, disturbances in self-identity, and social functioning. Despite the existence of evidence-based psychotherapeutic interventions for BPD, these interventions have important limitations (e.g., limited treatment efficacy). Furthermore, little evidence...
International Journal of Social Sciences and Management Review
2020
Nancy L. Morgan
10 citations
This paper introduces the potential benefits of utilizing an innovative, evidence-based framework to support clients' integration of their psychedelic experiences, while also presenting personal views and cautionary feedback offered by a sampling of practitioners, authors, and laypeople that have directly utilized psychedelics, and/or are working with clients utilizing psychedelics.The...
Pharmacotherapy in Psychiatry and Neurology
2020
Kamil Kozera, Lena Cichoń, Krzysztof M. Wilczyński et al.
MDMA (3,4-methylenedioxymethamphetamine) is a psychoactive substance classified as a hallucinogen. MDMA acts in the brain through a variety of neurochemical mechanisms, reducing anxiety, giving a sense of oneness with other people, expanding empathy, sharpening the senses and intensifying the experience of emotions. Therefore, the use of the MDMA assisted psychotherapy is being considered in...
edoc (University of Basel)
2020
Patrick Vizeli
Psychoactive substances such as the ring substituted phenylethylamine 3,4-methylenedioxymethamphetamine (MDMA; “ecstasy”) are widely used in recreational settings. Additionally, recent research highlights substance-assisted psychotherapy as potential new effective treatment for various psychiatric disorders, e.g. post-traumatic stress disorder (PTSD). MDMA releases and inhibits the uptake of...
The journal of psychedelic psychiatry
2020
George T Naratadam, Jason Narikkattu, Safeer Shah
Historical evidence has shown the potential efficacy of psychedelic drugs in the treatment of psychiatric diseases. Reporting psychedelic drug experiences in biomedical academic literature is critical to the progress of psychedelic psychiatry research and the potential implementation of psychedelics as therapeutics. Ayahuasca is a plant-based compound with hallucinogenic properties used by...
Journal of Contextual Behavioral Science
2020
Jordan Sloshower, Jeffrey Guss, Robert Krause et al.
168 citations
Abstract Psychedelic-assisted therapy is based on the premise that psychedelic substances can act as catalysts or adjuncts to psychotherapeutic processes. Recent clinical trials involving psychedelic-assisted therapy have generally employed a similar three-part structure consisting of preparation, support during the dosing sessions, and subsequent “integration.” However, the content of these...
Therapeutic Advances in Psychopharmacology
2020
Matthew Butler, Mathieu Seynaeve, Timothy R. Nicholson et al.
38 citations
Functional neurological disorder (FND), formerly known as conversion disorder, causes a high burden of disability and distress, and is amongst the most commonly encountered conditions in neurology clinics and neuropsychiatric services, yet the therapeutic evidence base is somewhat limited. There has been recent interest in the therapeutic potential of psychedelics such as psilocybin and...
Therapeutic Advances in Psychopharmacology
2020
Kim P. C. Kuypers
83 citations
Microdosing psychedelics is the repeated use of small doses of, for example, lysergic acid diethylamide (LSD) and psilocybin, typically for a few weeks. Despite the popular and scientific attention in recent years, and claims by users that it has therapeutic value in affective disorders like depression, little scientific knowledge is available to back this. The purpose of this review was to...
International Journal of Environmental Research and Public Health
December 12, 2019
Patricia P Wadowski, Georgiana-Aura Giurgea, Oliver Schlager et al.
Objective: N-(2-methoxy) benzyl-phenethylamine (NBOMe) derivatives have a high affinity to the serotonin receptor 2A and emerged as new psychedelic agents. We report the case of a 30-year-old man admitted to the hospital because of acute ischemia of the left arm with clinical symptoms of pallor, pulselessness, paresthesia, and a motoric deficit. The patient had a history of schizophrenia and...